'You give me fever!': are health services ready for immune cell engager therapy in advanced solid malignancies?
View/ Open
Date
2022-12-01ICR Author
Author
Pettinger, C
Livings, C
Grochot, R
Furness, A
Lopez, J
Type
Journal Article
Metadata
Show full item recordAbstract
Immune cell engager therapeutic strategies using bioengineered molecules to redirect immune cells into tumor are starting to demonstrate promising clinical activity in multiple early phase trials across numerous targets and a range of solid tumor types. These therapies, however, carry the risk of exaggerated cytokine-mediated on-target off-tumor adverse events that require highly specialized inpatient facilities. We report here the Royal Marsden experience of treating patients with advanced solid tumors on early phase immune engager clinical trials in a dedicated inpatient facility, focusing specifically on patterns of cytokine-mediated toxicity seen and proposing a risk-mitigation algorithm for the safe, feasible and scalable delivery of these therapies.
Collections
Subject
Clinical Trials as Topic
Immunotherapy
Humans
Immunotherapy
Neoplasms
Cytokines
Health Services
Research team
Skin Unit
Early Phase Drug Develop
Language
eng
Date accepted
2022-12-07
License start date
2022-12-01
Citation
Journal for ImmunoTherapy of Cancer, 2022, 10 (12), pp. e006073 - e006073
Publisher
BMJ PUBLISHING GROUP